These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35007790)

  • 1. Hypothalamic expression of huntingtin causes distinct metabolic changes in Huntington's disease mice.
    Dickson E; Soylu-Kucharz R; Petersén Å; Björkqvist M
    Mol Metab; 2022 Mar; 57():101439. PubMed ID: 35007790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of deletion of mutant huntingtin in steroidogenic factor 1 neurons on the psychiatric and metabolic phenotype in the BACHD mouse model of Huntington disease.
    Baldo B; Cheong RY; Petersén Å
    PLoS One; 2014; 9(10):e107691. PubMed ID: 25271967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic and behavioral effects of mutant huntingtin deletion in Sim1 neurons in the BACHD mouse model of Huntington's disease.
    Soylu-Kucharz R; Baldo B; Petersén Å
    Sci Rep; 2016 Jun; 6():28322. PubMed ID: 27334347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
    Dufour BD; McBride JL
    Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.
    Dai Y; Dudek NL; Li Q; Fowler SC; Muma NA
    J Neurosci; 2009 Sep; 29(37):11550-9. PubMed ID: 19759302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leptin deficiency reverses high metabolic state and weight loss without affecting central pathology in the R6/2 mouse model of Huntington's disease.
    Sjögren M; Soylu-Kucharz R; Dandunna U; Stan TL; Cavalera M; Sandelius Å; Zetterberg H; Björkqvist M
    Neurobiol Dis; 2019 Dec; 132():104560. PubMed ID: 31419548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance of basal levels of autophagy in Huntington's disease mouse models displaying metabolic dysfunction.
    Baldo B; Soylu R; Petersén A
    PLoS One; 2013; 8(12):e83050. PubMed ID: 24376631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/1 mouse model of Huntington's disease.
    Rattray I; Smith EJ; Crum WR; Walker TA; Gale R; Bates GP; Modo M
    PLoS One; 2013; 8(12):e84726. PubMed ID: 24367693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits.
    Hult S; Soylu R; Björklund T; Belgardt BF; Mauer J; Brüning JC; Kirik D; Petersén Å
    Cell Metab; 2011 Apr; 13(4):428-439. PubMed ID: 21459327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.
    Chen KP; Hua KF; Tsai FT; Lin TY; Cheng CY; Yang DI; Hsu HT; Ju TC
    J Neuroinflammation; 2022 Feb; 19(1):56. PubMed ID: 35219323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.
    Kumar A; Kneynsberg A; Tucholski J; Perry G; van Groen T; Detloff PJ; Lesort M
    Exp Neurol; 2012 Sep; 237(1):78-89. PubMed ID: 22698685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease.
    Hult Lundh S; Nilsson N; Soylu R; Kirik D; Petersén Å
    Hum Mol Genet; 2013 Sep; 22(17):3485-97. PubMed ID: 23697793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington's disease pathology.
    Savage JC; St-Pierre MK; Carrier M; El Hajj H; Novak SW; Sanchez MG; Cicchetti F; Tremblay MÈ
    J Neuroinflammation; 2020 Apr; 17(1):98. PubMed ID: 32241286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.
    Chan EY; Luthi-Carter R; Strand A; Solano SM; Hanson SA; DeJohn MM; Kooperberg C; Chase KO; DiFiglia M; Young AB; Leavitt BR; Cha JH; Aronin N; Hayden MR; Olson JM
    Hum Mol Genet; 2002 Aug; 11(17):1939-51. PubMed ID: 12165556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease.
    Tang B; Seredenina T; Coppola G; Kuhn A; Geschwind DH; Luthi-Carter R; Thomas EA
    Neurobiol Dis; 2011 Jun; 42(3):459-67. PubMed ID: 21334439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
    Kedaigle AJ; Reidling JC; Lim RG; Adam M; Wu J; Wassie B; Stocksdale JT; Casale MS; Fraenkel E; Thompson LM
    Hum Mol Genet; 2020 Jan; 29(2):202-215. PubMed ID: 31696228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of mutant huntingtin inactivation on Huntington disease-related behaviours in the BACHD mouse model.
    Cheong RY; Baldo B; Sajjad MU; Kirik D; Petersén Å
    Neuropathol Appl Neurobiol; 2021 Jun; 47(4):564-578. PubMed ID: 33330988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGF-1 protects against diabetic features in an in vivo model of Huntington's disease.
    Duarte AI; Petit GH; Ranganathan S; Li JY; Oliveira CR; Brundin P; Björkqvist M; Rego AC
    Exp Neurol; 2011 Oct; 231(2):314-9. PubMed ID: 21763311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
    Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
    Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.